Patients who are taking the highest approved dose of the cholesterol-lowering drug simvastatin may face increased risk for muscle injury compared with those taking lower doses or "possibly" other statins, the FDA warned on Friday.
189347 items (189347 unread) in 47 feeds
World Health Organization
(226 unread)
Media
(146550 unread)
Bird Flu
(3059 unread)
Diabetes
(8426 unread)
Cholesterol
(3564 unread)
Cancer
(15116 unread)
HIV
(7259 unread)
Women
(3814 unread)
Men
(1333 unread)
Patients who are taking the highest approved dose of the cholesterol-lowering drug simvastatin may face increased risk for muscle injury compared with those taking lower doses or "possibly" other statins, the FDA warned on Friday.